Sabcomeline (Memric; SB-202026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer’s disease. It made it to phase III clinical trials before being discontinued due to poor results.
This page contains content from the copyrighted Wikipedia article "Sabcomeline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
